Accro Raises $50 Million for Regulated Cell Death Drug Candidates

Accro Bioscience ( Suzhou ) raised more than $50 million in an oversubscribed Series B round to develop products based on the molecular mechanism of regulated cell death. Its portfolio of China Class 1.1 candidates include products for inflammatory, autoimmune and cancer indications. The company's research focuses on necroptosis, pyroptosis and ferroptosis, which are associated with major human diseases. The B round was led by Hongtai Aplus. Also participating were South China Venture apital, Shenzhen Capital Group and Suzhou Oriza Holdings.  More details.... Share this with colleagues: // //